Summit Therapeutics PLC (SMMT) — Cash Flow Reinvestment Rate
Summit Therapeutics PLC (SMMT) has a Cash Flow Reinvestment Rate of 152.67x as of December 2022, reinvesting $646.06 Million (capex $994.38K plus investments $-645.06 Million) from operating cash flow of $4.23 Million. Check how high is Summit Therapeutics PLC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Summit Therapeutics PLC Cash Flow Reinvestment Rate (2004–2016)
Historical reinvestment intensity for Summit Therapeutics PLC across 2 annual periods. Explore SMMT operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Summit Therapeutics PLC (2004–2016)
Year-by-year capital reinvestment analysis for Summit Therapeutics PLC. For live market cap and broader valuation context, see Summit Therapeutics PLC market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2016 | 0.01x | $209.99K | $15.18 Million | $110.00K | ▼ -96.9% |
| 2004 | 0.44x | $13.18K | $29.74K | $13.18K | — |